Objective Immune infiltration,as well as their implications across various cancers,and to establish a clinical prognostic model based on the findings.Methods The expression profile and clinical information of endometrial cancer tissue and adjacent tissues in TCGA endometrial cancer database were used,the differential expression genes were screened out for analysis,and the mRNA co-expressed by LncRNA was analyzed by GO enrichment and KEGG signaling pathway.The differential genes between endometrial cancer and adjacent tissues were intersected with the basement membrane protein genes.The selected differentially expressed genes were combined with survival status and survival time to screen out Hub genes by Lasso-cox regression analysis.Multivariate Cox regression analysis was used to establish a prognostic model,and pan-cancer analysis and immunoinfiltration correlation analysis were further performed.Results Six basal membrane protein Hub genes,ADAMTS5,EVA1C,THBS4,CTSD,ITGAV and LAMA1,were identified as associated with the prognosis of patients with endometrial cancer,and found that the survival rate of patients decreased significantly with the increase of risk score.Pan-cancer analysis found that these 6 genes were significantly different in most cancer types,and high expression in GBMLGG(glioma),LGG(low-grade glioma of the brain),LAML(acute myeloid leukemia),UVM(Uveal melanoma),ACC(adrenal cortical cancer)and other cancers had poor prognosis.The potential role of these genes in tumor immunotherapy was also explored,and significant negative correlation was found with Th 17 cells,Th2 cells,NK CD56 bright cells and other immune cells(P＜0.01),and significant positive correlation was found with Tcm,iDC,Eosinophils,aDC and other immune cells(P＜0.01).Conclusion Basal membrane protein gene has high clinical value in the diagnosis and prognosis of endometrial cancer,and can be used as a prognostic marker and potential therapeutic target for patients with endometrial cancer.

AIM: To study the efficacy and safety of dispersible formulation of levodopa-benserazide on the parkinson disease.　METHODS: The multicenter, open-label, self-controlled trial was conducted at 23 hospitals in 15 cities. Two hundred and four patients with idiopathic parkinson who had received standard levodopa-benserazide previously participated in this study. Dispersible levodopa-benserazide instead of standard levodopa-benserazide for 8 wk as a course. The Webster rating scale and patient diary were applied to assess the efficacy and safety of dispersible levodopa-benserazide.　RESULTS： The medication with dispersible levodopa-benserazide increased “on” time by 47 min, decreased “off” time by 11 min, and speeded the onset of “on” time by 37 min. The Webster score was improved by 25 %. Statistical significant difference was calculated (P<0.01). Slight and few adverse reactions were found.　CONCLUSION: Dispersible formulation of levodopa-benserazide is a powerful anti-parkinsonian drug characterized by oral easy use and rapid reach to therapeutic action after ingestion. This drug is particularly used in the parkinsonian patients with morning akinesia, delayed onset of “on” time, afternoon “off” status and dysphagia.

Gemcitabine is a new active drug in the treatment of advanced non small cell lung cancer (NSCLC). It is validated that the response rate of the single agent gemcitabine was consistently above 20%, median survival was 34 weeks and it could improve the disease related symptoms with well toleranced toxicities by many clinical studies. This report reviews the clinical studies of gemcitabine in the patients with advanced NSCLC.

Objective To study the therapeutic efficacy of dopaminergic agonists,? dihydroergocriptin(Cripar) by multiple center opened trial Methods Sixty cases of Parkinson's disease were divided into two groups: monotherapy group(27 cases) and combined therapy group(33 cases) The improvement in both groups after therapy was observed Results Patients undergone monotherapy were treated with ? dihydroergocriptin and those undergone combined therapy were treated with combined use of ? dihydroergocriptin and L doparmine All patients after treatment showed improvement of clinical symptoms There were 7 patients (28 0%) in the monotherapy group and 13 patients (39 4%) in the combined therapy group markedly improved Evaluation of therapeutic improvement by modified UPDRS revealed that the average scores was 5 01 in monotherapy group and was 6 39( P